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OBJECTIVE — Injected volume and subcutaneous adipose tissue blood ﬂow (ATBF) affect
insulin absorption. Pharmacokinetics of short-acting insulin analogs were established by assess-
ing injection of small doses in lean subjects, healthy or with type 1 diabetes. In obese patients,
however, daily dosages are larger and ATBF is decreased. This study assessed the kinetics of a
short-acting insulin analog in obese subjects with type 2 diabetes.
RESEARCH DESIGN AND METHODS — Euglycemic clamps after subcutaneous lis-
pro injections were performed. Six healthy control subjects received 10 units. Seven obese (BMI
38.37.0kg/m
2)subjectswithtype2diabetesreceived10,30,and50units.Plasmalisprowas
measured by speciﬁc radioimmunoassay and ATBF by the
133Xe-washout technique.
RESULTS — ATBF was 64% lower in subjects with type 2 diabetes than in control subjects.
After10unitsinjection,timetolisproplasmapeak(Tmax)wassimilar(48.3vs.55.7min;control
subjects versus type 2 diabetic subjects), although maximal concentration (Cmax)/dose was 41%
lower in subjects with type 2 diabetes, with lower and delayed maximal glucose infusion rate
(GIRmax:9.0vs.0.6mg/kg/min,P0.0001,69vs.130min,P0.0001,respectively).After30-
and50-unitinjections,Tmax(88.6and130.0min,respectively)andtimetoGIRmax(175and245
min) were further delayed and dose related (r
2  0.51, P  0.0004 and r
2  0.76, P  0.0001,
respectively).
CONCLUSIONS — Absorption and hypoglycemic action of increasing dosages of lispro are
critically delayed in obese subjects with type 2 diabetes.
Diabetes Care 33:2502–2507, 2010
T
he general purpose of intensive
insulin regimens is to achieve post-
prandial glucose control. Short-
acting insulin analogs were originally
designed to ﬁt this premise by synchro-
nizing plasma insulin increase and food
absorption (1). They are indeed absorbed
morequicklythanregularhumaninsulin.
However, this was demonstrated in nor-
mal-weight healthy subjects or lean sub-
jects with type 1 diabetes in studies
assessing small subcutaneous injections
(i.e., 4–12 units) (2–4). Paradoxically,
few studies (5,6) have either assessed
such dosages or been conducted in over-
weight subjects with or without type 2
diabetes, although clinical practice shows
that most patients with type 2 diabetes on
insulin are distinctly overweight or obese
and on much larger insulin dosages (7,8).
Multiple factors affect insulin absorp-
tion including its physicochemical prop-
erties, excipients, concentration, and
dosage as well as the clinical conditions
underwhichitisinjected,e.g.,orthostatic
position, injection site, depth, exercises,
massage, temperature, and smoking
(1,4,9,10).Injectedvolume(11)andsub-
cutaneous adipose tissue blood ﬂow
(ATBF) are two other major absorption
factors (12,13). Although it is well recog-
nized that ATBF is dramatically altered in
obese insulin-resistant individuals and in
subjects with type 2 diabetes, baseline
values are 50–70% lower than values for
lean healthy subjects and physiological
postprandialdoublingisblunted(14,15).
Nonetheless,moststudieshavebeencon-
ducted in lean subjects.
Inviewoftheabove,wehypothesized
that absorption rate and activity of short-
acting insulin analogs would be substan-
tially lower in obese subjects with type 2
diabetes than pharmacokinetics reported
in the literature. This study thus assessed
the pharmacokinetic and pharmacody-
namic responses of obese subjects with
type 2 diabetes to subcutaneous injec-
tionsoflisproatincrementallylargerdos-
ages (10, 30, and 50 units) during
euglycemic clamps.
RESEARCH DESIGN AND
METHODS
Study design
This single-dose single-blinded con-
trolled three-way randomized sequential
study in subjects with type 2 diabetes was
conducted at the clinical research center.
Nonsmoking patients aged 18–75
years, with a BMI 30 kg/m
2 and an A1C
10%, taking over 100 units insulin
daily, with or without oral hypoglycemic
agents, were recruited. All were asked to
maintain a stable diet and physical activ-
ity level between experiments and to re-
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and caffeine intake for 48 h before each
experiment.
The experimental protocol was duly
approved by the Research Ethics Com-
mittee, conducted according to the Dec-
laration of Helsinki principles, and all
subjects signed the consent form.
Protocol
Experiments were performed 3 weeks
apart in randomized order (10, 30, or 50
units). Subjects with type 2 diabetes were
admitted at 8:00 P.M. on the evening pre-
ceding each experimental day, after hav-
ing their evening meal and their usual
insulin injection. An intravenous antecu-
bital cannula was inserted into each arm:
one for venous sampling and glucose
measurements (Beckman Instruments,
Diagnostic Systems Group, Brea, CA) and
the other for dual administration of hu-
man insulin (Toronto R, Novo Nordisk
Canada, Mississauga, ON) and dextrose
as needed. Plasma glucose level was
broughtprogressivelyintothenormaltar-
get range (i.e., 5–6 mmol/l overnight).
Experiments started at 8:00 A.M. An-
thropometric data were recorded: height,
weight, and body composition by bioel-
ectrical impedance (Tanita, Arlington
Heights, IL). Subjects were kept fasting
(drinkingwaterpermitted)duringtheen-
tire 8-h clamp study. A venous catheter
wasretrogradelyinsertedintothehandof
the same arm used for nighttime blood
samplings, with the hand kept warm in a
heating pad. Euglycemic clamp was per-
formed after subcutaneous injection of
lispro, 20 min after interruption of the
overnightinsulininfusion.Lisprowasad-
ministered with a pen device (HumaPen-
Ergo,EliLillyCanada,Toronto,ON)with
an 8-mm needle (30 G  0.3  8 mm)
into subcutaneous adipose tissue 8 cm
above the umbilicus and 10 cm from the
medial line.
Plasma glucose was measured every 5
min to clamp glucose levels between 5
and 6 mmol/l with a 20% dextrose infu-
sionviatheantecubitalcatheteralreadyin
place. Blood samples were collected at
10-min intervals for the ﬁrst 3 h and at
20-min intervals thereafter. Study proce-
duresendedat4:00 P.M.Subjectsreceived
a meal and their usual dose of insulin.
They were discharged once glucose stabi-
lized over 6 mmol/l.
Healthy control subjects were admit-
ted on the experimental day at 7:30 A.M.,
fasting from 8:00 P.M. the prior evening.
Each received a single dose 10 units lis-
pro;allotherprocedureswereidenticalto
those described above.
ATBFwasmeasuredonce,ontheﬁrst
experimental day, in each subject using
the gold standard method, i.e., the
133Xe
washouttechnique,aroutinelyusedtech-
nique in our hands (16). Brieﬂy,
133Xe
(Bristol-Myers Squibb Canada, Dorval,
Quebec) was injected in the subcutane-
ous adipose tissue of the abdomen, at the
opposite side of the insulin injection site.
ATBF was measured quantitatively using
a Mediscint System (John Caunt Scien-
tiﬁc, Oxford, U.K.).
Sample analysis
Blood samples were collected in tubes
containing sodium citrate and a protease
inhibitor cocktail (Complete, EDTA-free;
Roche Diagnostics, Mannheim, Ger-
many). Blood was promptly centrifuged
at 4°C, and the resultant plasma aliquots
were frozen immediately in liquid nitro-
gen and stored at 80°C until assaying.
Plasma lispro was measured in duplicate
with a speciﬁc radioimmunoassay kit
(Linco Research, St. Charles, MO).
Calculations and statistical analyses
Plasmalispromeasurementswereusedto
estimate absorption rate constant (ka),
maximum plasma concentration (Cmax),
time to maximal concentration (Tmax),
area under the lispro plasma concentra-
tion curve (AUC0-), Cmax to dose ratio
(Cmax/D), AUC0- to dose ratio (AUC0-/
D),volumeofdistribution(Vz),clearance
(Cl), half-life (t1⁄2), and mean residence
time. Calculations were performed as-
suming a noncompartmental distribution
using the WinNonlin 5.2 software (Phar-
sight, Mountain View, CA).
Usingglucoseinfusionrate(GIR)ver-
sus time data, the maximum glucose in-
fusion rate (GIRmax), time to maximum
glucose infusion rate (tGIRmax), and total
glucose infusion from injection to end of
clamp (GItot) were calculated.
The study comprised one experiment
in healthy subjects and three in obese
subjects with type 2 diabetes; in the latter
subjects, 10-unit experiments were used
ascontrolforcomparisonwithlargerdos-
ages. Results not normally distributed,
based on the Normal Quintile Plot, were
log-transformed for all statistical analyses
and reported back-transformed in their
original units. Values of P  0.05 were
considered signiﬁcant.
Fisher exact tests, for categorical vari-
ables,andunpairedttests,forcontinuous
variables, were used to compare charac-
teristics between groups. Unpaired t tests
were used for comparison between
groups of pharmacokinetic and pharma-
codynamic variables with 10-unit injec-
tions. Repeated-measures ANOVA tests
wereusedtocomparedifferencesinphar-
macokinetic and pharmacodynamic vari-
ables at different dosages in subjects with
type 2 diabetes, with Tukey honestly sig-
niﬁcance difference tests for post hoc
multiple comparisons.
For correlations between parameters
that were repeatedly assessed at multiple
insulin dosages in the same patients, re-
peated-measures ANOVA tests consider-
ing clustering of multiple measurements
were used. All adjustments were per-
formed again by multivariate ANOVA
tests. Data calculations and statistical
analyses were performed using JMP 7.0
software (SAS Institute, Cary, NC).
RESULTS— Six healthy subjects and
seven obese subjects with type 2 diabetes
wereenrolled(A1C8.11.2%,duration
of diabetes 20.2  8.6 years, insulin ther-
apy5.14.2years).Subjectswithtype2
diabetes participated in all three experi-
ments (10, 30, and 50 units). Their age,
BMI, weight, and adiposity indexes were
higheralthoughATBFwasblunted(Table
1). Heart rate, blood pressure, and ATBF
remainedstableinbothgroupsduringex-
periments (data not shown).
After the 10-unit injection, the ratio
Cmax/D was 41% lower (P  0.001) in
subjects with type 2 diabetes than in
healthy subjects, but Cmax, Tmax, AUC0-,
AUC0-/D,ka,andClweresimilarinboth
groups. Mean residence time, Vz, and t1⁄2
tended to be greater in subjects with type
2diabetesthanincontrolsubjects(Fig.1,
Table 2). After the 30- and 50-unit injec-
tions, ka dropped by 60% (P  0.035)
and Tmax was delayed by 33 (P  0.118)
and 74 min (P  0.001), respectively.
Cmax/D, Cl, Vz, and t1⁄2 were not af-
fected by the dose, although mean resi-
dence time tended to be greater. Tmax
(r
20.51,P0.0004),Cmax(r
20.90,
P0.0001),andAUC0-(r
20.94,P
0.0001) were associated with dosage.
The glucodynamic differences be-
tweenhealthysubjectsandtype2diabetic
subjects after 10 units of lispro were con-
siderable (Fig. 2, Table 2). GIRmax and
GItot were, respectively, 7% (P  0.0001)
and 4% (P  0.0001) of the value mea-
sured in healthy subjects, and tGIRmax
was prolonged by1h( P  0.0001). After
the 30- and 50-unit injections, GIRmax
and GItot were different from the 10-unit
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50-unit lispro injection, tGIRmax was
longer than after the 10- and 30-unit in-
jections (P  0.002). GIRmax (r
2  0.67,
P  0.0001), GItot (r
2  0.73, P 
0.0001), and tGIRmax (r
2  0.76, P 
0.0001) were strongly correlated with
dosage. After the 10-unit injection, the
average difference between Tmax and
tGIRmax was 19 min in healthy subjects
and 74 min (P  0.0007) in subjects with
type2diabetes.Thegapincreasedfurther
when subjects received 30 and 50 units
(86 and 115 min, respectively).
When GIR was plotted as a function
of lispro plasma concentrations, the se-
quentialresponse-concentrationrelation-
ship depicted a counterclockwise
hysteresis for both healthy subjects and
subjects with type 2 diabetes (Fig. 3). In
healthy subjects receiving 10 units of in-
sulin, an initial GIR response of 2.22 mg/
kg/min was seen with insulin
concentrations nearing 40 pmol/l. There-
after, large increases of insulin concentra-
tions were required to increase GIR,
althoughoncetheresponsewastriggered,
it was maintained while plasma concen-
trations decreased to 20% of the Cmax.I n
obesesubjectswithtype2diabetes,aftera
10-unit injection, much greater concen-
trations of insulin were required to pro-
duce even a minimal effect (e.g., 273
pmol/l of insulin elicited a GIR of 0.1 mg/
kg/min). The response later increased
abruptly to attain GIRmax when plasma
concentrations of insulin were already
dropping; once GIRmax was attained, the
response decreased linearly with insulin
plasma concentrations. The same pattern
was observed for 30- and 50-unit
injections.
CONCLUSIONS — This study char-
acterizes the pharmacokinetic and phar-
macodynamic proprieties of the short-
acting insulin analog lispro in obese
subjects with type 2 diabetes. After low-
dose injection (10 units), lispro absorp-
tion in subjects with type 2 diabetes was
as comparable as in control subjects, al-
though the hypoglycemic effect was
blunted. However, both absorption and
activity were severely delayed and
blunted at higher dosages (30 and 50
units) in subjects with type 2 diabetes,
featuring a dose-response effect. Kinetic
and dynamic parameters estimated in
control subjects conﬁrmed those pub-
lished elsewhere (2–4) and support the
value of our ﬁndings.
Ithasbeenrepeatedlyproposed,from
correlations with pharmacokinetic pa-
rameters,thatsubcutaneousfatthickness,
obesity, and low ATBF reduce insulin ab-
sorption (12,13). Conversely, the present
study does not conﬁrm these facts when
small dosages are administered. Insulin
Vz and Cl depend on fat-free mass (17).
Conversely, adipose tissue is essentially
waterfree.Therefore,higherfat-freemass
and total body water in our subjects with
Table 1—Characteristics of study groups
Healthy subjects Subjects with type 2 diabetes P
n (men/women) 6 (3/3) 7 (6/1) 0.266
Age (years) 23.7  2.4 60.3  7.6 0.0001
BMI (kg/m
2) 22.1  1.4 38.3  7.0 0.0002
Weight (kg) 70.0  7.6 111.0  14.3 0.0002
Fat (%) 22.4  7.9 32.6  5.1 0.017
Fat mass (kg) 15.4  4.5 36.5  9.6 0.0005
Fat-free mass (kg) 54.6  10.2 74.5  7.7 0.002
Total body water (kg) 40.0  7.5 54.5  5.7 0.002
ATBF (ml/min/100 g tissue) 4.2  0.7 1.5  0.5 0.0001
Data are means  SD.
Figure 1—Mean ( SD) plasma lispro concentration over 480-min euglycemic clamps after subcutaneous injection of 10 units in healthy subjects
(F) and 10 units (E), 30 units ( ), and 50 units (‚) in obese subjects with type 2 diabetes.
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ment tendency in Vz, which should ac-
countforthedecreaseinCmaxandCmax/D
when comparing with control subjects.
Withinourobesesubjectswithtype2
diabetes presenting high daily insulin
needs, we indeed expected to observe a
blunted pharmacodynamic proﬁle com-
pared with control subjects. Moreover,
we showed a dose-dependent delay of
Tmax and GIRmax at high doses in obese
type 2 diabetic subjects. Similar results
were found in a study done with healthy
subjectsusinglowerlisprodoses(18)and
in another study using inhaled insulin
in subjects with type 1 diabetes (19).
These effects observed at lower dose were
expected to be more pronounced with
higher doses in insulin-resistant subjects.
Interindividual variation in insulin re-
quirements was evaluated in overweight
subjects with type 2 diabetes (20). The
8-h clamp period was not long enough to
determine the entire absorption and ac-
tion proﬁle of 36 units of regular human
insulin. Authors attributed these results
to the possible slow insulin absorption in
Table 2—Pharmacokinetic and pharmacodynamic parameters after subcutaneous injection of lispro
Healthy subjects
(10 units)
Subjects with type 2
diabetes (10 units)
Subjects with type 2
diabetes (30 units)
Subjects with type 2
diabetes (50 units)
ka (min) 0.0531  0.0236 0.0455  0.0242 0.0184  0.0076§ 0.0179  0.0091§
Tmax (min) 48.3  4.1 55.7  14.0 88.6  21.9 130. 0  46.0 ¶
Cmax (pmol/l) 523  42 310  28 808  218  1,313  346 #
Cmax/D (liters) 0.0091  0.0007 0.0054  0.0005† 0.0047  0.0012 0.0046  0.0012
AUC0- (pmol/min/l) 68,462  17,346 60,683  15,191 192,155  46,873  372,571  59,578 #
AUC0-/D (min/l) 1.190  0.302 1.056  0.264 1.140  0.188 1.296  0.208
Vz (liters) 67  16 118  34 104  53 107  46
Cl (l/min) 0.88  0.21 0.99  0.22 0.90  0.14 0.79  0.13
t1⁄2 (min) 67  15 100  34 97  38 136  72
Mean resistance time (min) 119  21 180  65 196  30 236  49
tGIRmax (min) 69  12 130  23‡ 175  21 245  64 #
GIRmax* (mg/kg/min) 9.0 (7.1–11.4) 0.6 (0.4–0.9)‡ 2.0 (1.4–2.7)  2.5 (1.7–3.7) 
GItot* (mg/kg) 2,299 (1,881–2,811) 92 (49–174)‡ 364 (249–533)  678 (462–994) 
DataaremeansSDunlessotherwiseindicated.Therewere10unitsadministeredinhealthysubjectsand10,30,and50unitsinobesesubjectswithtype2diabetes.
*Geometric means with 95% CI; †P  0.001 compared with healthy controls using unpaired t test; ‡P  0.0001 compared with healthy controls using unpaired
ttest;§P0.04comparedwith10unitsinsubjectswithtype2diabetesusingrepeated-measuresANOVA; P0.002comparedwith10unitsinsubjectswithtype
2 diabetes using repeated-measures ANOVA; ¶P  0.05 compared with 30 units in subjects with type 2 diabetes using repeated-measures ANOVA; #P  0.002
compared with 30 units in subjects with type 2 diabetes using repeated-measures ANOVA.
Figure2—Glucoseinfusionrateover480-mineuglycemicclampsaftersubcutaneousinjectionof10unitsinhealthysubjects( )and10units(f),
30 units (p), and 50 units (o) in obese subjects with type 2 diabetes.
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decreasing insulin absorption with in-
creasing doses. They also correlated the
absorbed insulin amount to daily insulin
requirements.Herein,atlowdosage,wedid
not observe a slower absorption of lispro in
obese subjects with type 2 diabetes, but in-
deed conﬁrmed that higher doses have a
reducedeffect.Thus,inobesesubjectswith
type 2 diabetes, as ours, high insulin needs
may account in part for low absorption ef-
ﬁciency with high doses.
As shown in Fig. 3, both groups ex-
hibited a counterclockwise hysteresis, al-
though the magnitude was severely
blunted in subjects with type 2 diabetes
after 10-, 30-, and 50-unit injections.
Meanwhile, GIR remained low compared
with control subjects. These ﬁndings il-
lustrate the insulin resistance expected in
our obese subjects with type 2 diabetes.
Fast prandial rise in plasma and fast
action of insulin are both key to adequate
postprandial metabolic control. The im-
portance of determining whether short-
acting insulin analogs are efﬁcient was
recently brought into question (21–23).
Several studies (rev. in 22) have noted no
or few beneﬁts for these analogs relatively
to human insulin in patients with type 2
diabetes as opposed to type 1 diabetes.
Recent large studies (24,25) provided no
evidence supporting the use of prepran-
dial insulins compared with basal insu-
lins. The prolonged time-action proﬁle of
short-actinginsulinanalogsshowninthis
study could provide an explanation to
whypreprandialinsulinshavenothadthe
expected beneﬁts. In daily life, the delay
in pharmacodynamic responses after
short-acting analog injections may ham-
per postprandial metabolic control, espe-
cially when large dosages are used.
The limitation of this study relates to
the impossibility to distinguish between
group and dose effect, since high dosages
were not tested in the control group. Test-
ing high dosages in control subjects would
indeed require intensive care management.
In summary, this study shows that
absorption and hypoglycemic action of
short-acting insulin analogs are critically
delayedatincrementallylargerdosagesin
obese subjects with type 2 diabetes.
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